iPRIME is an ovarian cancer clinical trial that tests how safe and effective the combination treatment of durvalumab and tremelimumab with standard chemotherapy can be as a treatment for newly diagnosed patients with ovarian, fallopian tube or peritoneal cancers.
ANZGOG spoke with iPRIME Principal Investigator, Associate Professor Tarek Meniawy, as the study has reached its recruitment milestone.
Assoc Prof Tarek Meniawy is also an ANZGOG Director and Chair of ANZGOG’s Ovarian Tumour Type Working Group
As the Principal Investigator (PI) what are you trying to achieve with the iPRIME study?
The purpose of iPRIME is to try and better understand the role for immunotherapy in ovarian cancer. Other trials looking at immunotherapy alone or combinations with chemotherapy in the first line setting have not shown a significant benefit and it is hoped that by testing the combination of chemotherapy and dual-agent immunotherapy then we may be able to find patients who are more likely to benefit from treatment.
What are the next steps with this research?
The next steps with this research will involve reflecting on the outcomes of the study, and planning what the ‘next question’ that will no doubt need answering. This will also be supported by the translational studies as mentioned above. Overall, we hope that the results may increase the knowledge about the role of immunotherapy and help design future clinical trials to build on the knowledge from existing evidence.
What is your message to the patients of iPRIME?
I am very grateful for all the patients that were part of iPRIME who have committed their time and effort to be part of this study, and for the confidence they have placed in ANZGOG researchers as well as their local trials team to be part of this study. This important Australian trial is one of the first studies internationally to examine dual immunotherapy with chemotherapy. This sort of research is not possible without the support and preservation of patients and their support networks.
Want to know more about ANZGOG’s clinical trials?
To find out more about ANZGOG’s clinical trials, click here.
